Recombinant Human Thrombopoietin Injection Application Scope

Recombinant Human Thrombopoietin Injection is primarily used for the treatment of thrombocytopenia (low platelet count) in patients with various conditions such as idiopathic thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia, and bone marrow failure syndromes.

This treatment stimulates the production of platelets in the bone marrow by mimicking the activity of the natural thrombopoietin hormone, which is responsible for regulating platelet production. It is especially useful in patients who do not respond adequately to traditional treatments such as corticosteroids or immunosuppressive therapy.

Recombinant Human Thrombopoietin Injection Characteristics

Ingredients:
- Active ingredient: Recombinant human thrombopoietin (rhTPO)
- Excipients: Sodium chloride, water for injection, and stabilizers.
Properties:Recombinant Human Thrombopoietin is a recombinant glycoprotein that mimics the natural hormone thrombopoietin. It stimulates megakaryocyte differentiation and platelet production, which helps in increasing platelet counts in patients with low platelet counts due to various conditions.
Specification:Available in single-use vials containing 10 μg/0.5 mL or 50 μg/1 mL of the active ingredient for intravenous or subcutaneous use.
Storage:
- Store at 2°C to 8°C (36°F to 46°F). Do not freeze.
- Protect from light and store in the original packaging to maintain drug potency.
Expiry Date:Typically 24 months from the manufacturing date (check packaging for exact expiry dates).
Executive Standard:Meets the FDA or other local health authority standards for recombinant biologic drugs.
Approval Number:Specific approval number from the FDA or other relevant regulatory bodies.
Manufacturer:Manufacturer information may vary by region, typically produced by major pharmaceutical companies specializing in biologics.

Guidelines For The Use Of Recombinant Human Thrombopoietin Injection

Dosage and Administration:

For ITP: The recommended initial dose is usually 1-3 μg/kg body weight per day, administered subcutaneously or intravenously.
For chemotherapy-induced thrombocytopenia, the dosing regimen can vary based on platelet count and clinical response, typically administered during or after chemotherapy cycles.

Adverse Reactions:

Common side effects include headache, dizziness, injection site reactions, fever, and fatigue.
Serious side effects are rare but may include thromboembolic events (such as stroke or deep vein thrombosis) due to excessive platelet production.

Medication Limitations

Contraindications:

Hypersensitivity to recombinant thrombopoietin or any component of the formulation.
Contraindicated in patients with active thrombosis or conditions that predispose them to thrombotic events.

Precautions:

Monitor for signs of thromboembolism during treatment.
Liver and kidney function should be monitored in patients with pre-existing conditions, as these organs metabolize the drug.

Recombinant Human Thrombopoietin Injection Interactions

Drug Interactions: Care should be taken when used with other bone marrow-stimulating agents or antiplatelet drugs, as this could lead to excessive platelet counts or bleeding complications.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.